{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.011","value":"0.84"},{"groupId":"OG001","spread":"0.011","value":"0.83"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"293"},{"groupId":"OG001","value":"287"}],"units":"Participants"}],"title":"Cycle 1 (Baseline)"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.011","value":"0.83"},{"groupId":"OG001","spread":"0.011","value":"0.84"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"255"},{"groupId":"OG001","value":"271"}],"units":"Participants"}],"title":"Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.013","value":"0.80"},{"groupId":"OG001","spread":"0.012","value":"0.82"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"235"},{"groupId":"OG001","value":"267"}],"units":"Participants"}],"title":"Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.014","value":"0.77"},{"groupId":"OG001","spread":"0.011","value":"0.84"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"231"},{"groupId":"OG001","value":"245"}],"units":"Participants"}],"title":"Cycle 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.016","value":"0.77"},{"groupId":"OG001","spread":"0.013","value":"0.84"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"218"},{"groupId":"OG001","value":"230"}],"units":"Participants"}],"title":"Cycle 5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.016","value":"0.78"},{"groupId":"OG001","spread":"0.012","value":"0.85"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"211"},{"groupId":"OG001","value":"234"}],"units":"Participants"}],"title":"Cycle 6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.016","value":"0.77"},{"groupId":"OG001","spread":"0.014","value":"0.83"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"199"},{"groupId":"OG001","value":"216"}],"units":"Participants"}],"title":"Cycle 7"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.015","value":"0.80"},{"groupId":"OG001","spread":"0.013","value":"0.84"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"185"},{"groupId":"OG001","value":"207"}],"units":"Participants"}],"title":"Cycle 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.015","value":"0.81"},{"groupId":"OG001","spread":"0.013","value":"0.85"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"174"},{"groupId":"OG001","value":"202"}],"units":"Participants"}],"title":"Cycle 9"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.017","value":"0.75"},{"groupId":"OG001","spread":"0.015","value":"0.83"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"250"},{"groupId":"OG001","value":"245"}],"units":"Participants"}],"title":"EOT"}],"denoms":[{"counts":[{"groupId":"OG000","value":"309"},{"groupId":"OG001","value":"306"}],"units":"Participants"}],"description":"Patient-reported outcomes (PROs) assessed health-related quality of life (QoL) by the EuroQoL Group health status questionnaire (EQ-5D), which was a brief self-administered, validated instrument with 2 parts. In this outcome measure, the first part with 5 descriptors of current health state (mobility, self-care, usual activities, pain/discomfort, \\& anxiety/depression) was used; a participant was asked to rate each state on a 3-level scale (1=no problem, 2=some problem, \\& 3=extreme problem); higher levels indicated greater severity/impairment. The published weights allowed the creation of a single summary score called the EQ-5D index, which ranged from -0.594 to 1; low scores represented a higher level of dysfunction \\& 1 as perfect health.","dispersionType":"Standard Error","groups":[{"description":"Participants received Sunitinib on 9 6-week cycles on 4/2 dosing schedule: 4 weeks on, 2 weeks off.","id":"OG000","title":"Sunitinib"},{"description":"Participants received Placebo on 9 6-week cycles with 4/2 dosing schedule: 4 weeks on, 2 weeks off.","id":"OG001","title":"Placebo"}],"paramType":"MEAN","populationDescription":"ITT population included all participants who were randomized, with study drug assignment designated according to initial randomization, regardless of whether participants received study drug or a different drug from that to which they were randomized. Here, 'Number analyzed' signifies the number of participants evaluable at specified time-points.","reportingStatus":"POSTED","timeFrame":"Cycle 1(Day 1); subsequent cycles (Day 1) and end of treatment/withdrawal (ie, up to 1 year)","title":"PROs- EuroQoL EQ-5D Observed Means - Intent to Treat Population","type":"SECONDARY","unitOfMeasure":"Units on a scale"}